KR20190072579A - 폴리믹신-알기네이트 올리고머 콘주게이트 - Google Patents

폴리믹신-알기네이트 올리고머 콘주게이트 Download PDF

Info

Publication number
KR20190072579A
KR20190072579A KR1020197014050A KR20197014050A KR20190072579A KR 20190072579 A KR20190072579 A KR 20190072579A KR 1020197014050 A KR1020197014050 A KR 1020197014050A KR 20197014050 A KR20197014050 A KR 20197014050A KR 20190072579 A KR20190072579 A KR 20190072579A
Authority
KR
South Korea
Prior art keywords
polymyxin
alginate oligomer
alginate
conjugate
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197014050A
Other languages
English (en)
Korean (ko)
Inventor
일레인 퍼거슨
데이비드 윌리엄 토마스
아르네 데센
필립 라이
Original Assignee
알지파마 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617860.0A external-priority patent/GB201617860D0/en
Priority claimed from GBGB1714710.9A external-priority patent/GB201714710D0/en
Application filed by 알지파마 에이에스 filed Critical 알지파마 에이에스
Publication of KR20190072579A publication Critical patent/KR20190072579A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020197014050A 2016-10-21 2017-10-20 폴리믹신-알기네이트 올리고머 콘주게이트 Abandoned KR20190072579A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1617860.0 2016-10-21
GBGB1617860.0A GB201617860D0 (en) 2016-10-21 2016-10-21 Polymyxin-alginate oligomer conjugates
GBGB1714710.9A GB201714710D0 (en) 2017-09-13 2017-09-13 Polymyxin-alginate oligomer conjugates
GB1714710.9 2017-09-13
PCT/EP2017/076927 WO2018073449A1 (en) 2016-10-21 2017-10-20 Polymyxin-alginate oligomer conjugates

Publications (1)

Publication Number Publication Date
KR20190072579A true KR20190072579A (ko) 2019-06-25

Family

ID=60186268

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014050A Abandoned KR20190072579A (ko) 2016-10-21 2017-10-20 폴리믹신-알기네이트 올리고머 콘주게이트

Country Status (13)

Country Link
US (1) US20190328833A1 (enExample)
EP (1) EP3528830B1 (enExample)
JP (1) JP2020503253A (enExample)
KR (1) KR20190072579A (enExample)
CN (1) CN109843315A (enExample)
AU (1) AU2017345295A1 (enExample)
BR (1) BR112019007927A2 (enExample)
CA (1) CA3040795A1 (enExample)
DK (1) DK3528830T3 (enExample)
ES (1) ES2933983T3 (enExample)
FI (1) FI3528830T3 (enExample)
RU (1) RU2019109719A (enExample)
WO (1) WO2018073449A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003311B (zh) * 2019-12-14 2024-04-19 乔杜里·马努 降低多器官毒性的多元药物制剂
US20230141981A1 (en) * 2020-01-21 2023-05-11 Shanghai Micurx Pharmaceuticals Co., Ltd Novel compounds and composition for targeted therapy of kidney-associated cancers
US12037631B2 (en) * 2020-10-06 2024-07-16 City University Of Hong Kong System and method for detecting a target enzyme
CN113081956A (zh) * 2021-04-12 2021-07-09 青岛大学附属医院 一种氧化海藻酸钠改性的那他霉素滴眼液及其制备方法
CN113069556B (zh) * 2021-04-12 2022-04-08 青岛大学附属医院 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法
US20240376155A1 (en) * 2021-07-21 2024-11-14 Shanghai Micurx Pharmaceutical Co., Ltd. Novel compounds and compositions for targeted therapy of renal cancers
EP4373836A4 (en) * 2021-07-21 2025-10-22 Shanghai Micurx Pharmaceutical Co Ltd COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF KIDNEY DISEASES
CN114009731B (zh) * 2021-11-05 2024-01-02 恒枫食品科技有限公司 一种茶风味基料及其制备方法、应用
CN114752535A (zh) * 2022-05-16 2022-07-15 北京昊峰节能环保科技有限公司 一种总石油烃污染地下水生物修复剂及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB976301A (en) * 1960-10-27 1964-11-25 Calmic Ltd Preparation and use of alginates
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
IL96326A (en) * 1989-11-15 1995-07-31 Sandoz Ag Polymyxin conjugates, their preparation and pharmaceutical preparations containing them
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
PT2268142T (pt) * 2007-11-27 2017-06-02 Algipharma As Utilização de oligómeros alginados no combate aos biofilmes
RU2586253C2 (ru) * 2009-06-03 2016-06-10 АльгиФарма АС Обработка акинетобактерий альгинатными олигомерами и антибиотиками

Also Published As

Publication number Publication date
RU2019109719A (ru) 2020-11-24
WO2018073449A1 (en) 2018-04-26
CA3040795A1 (en) 2018-04-26
FI3528830T3 (fi) 2023-01-13
EP3528830B1 (en) 2022-10-05
EP3528830A1 (en) 2019-08-28
RU2019109719A3 (enExample) 2021-02-20
US20190328833A1 (en) 2019-10-31
BR112019007927A2 (pt) 2019-07-02
CN109843315A (zh) 2019-06-04
DK3528830T3 (da) 2022-12-19
JP2020503253A (ja) 2020-01-30
AU2017345295A1 (en) 2019-05-02
ES2933983T3 (es) 2023-02-15

Similar Documents

Publication Publication Date Title
KR20190072579A (ko) 폴리믹신-알기네이트 올리고머 콘주게이트
KR20190070946A (ko) 바시트라신-알기네이트 올리고머 콘주게이트
ES2565564T3 (es) Una composición que comprende un antibiótico y un dispersante
CN102458474B (zh) 使用藻酸盐低聚物和抗生素治疗不动杆菌
EP1392329B1 (en) Use of sulodexide for the treatment of inflammatory bowel disease
US10967065B2 (en) Compounds for treating biofilm infection
WO2023001264A1 (zh) 一种能皮下给药的抗生素药物组合物
US20200390868A1 (en) Anti-viral therapeutic for infection of the eye
EP3662924A1 (en) Compositions for treating lung infections by airway administration
HK40004581A (en) Bacitracin-alginate oligomer conjugates
HK40004580A (en) Polymyxin-alginate oligomer conjugates
US20250352663A1 (en) Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use
Sun et al. Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904